rolinsatamab talirine (ABBV-176) / AbbVie - LARVOL DELTA

Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies. (PubMed, Front Endocrinol (Lausanne)) - "Different strategies have been developed to target this receptor including modification of PRL peptides (Del1-9-G129R-hPRL, G129R-Prl), growth hormone receptor/prolactin receptor bispecific antibody antagonist, neutralizing antibody LFA102, an antibody-drug conjugate (ABBV-176) of the humanized antibody h16f (PR-1594804) and pyrrolobenzodiazepine dimer, a bispecific antibody targeting both PRLR and CD3, an in vivo half-life extended fusion protein containing PRLR antagonist PrlRA and albumin binding domain...Recently, using structure-based virtual screening, we identified a few antipsychotic drugs including penfluridol as a molecule that inhibits PRL-signaling to inhibit PDAC tumor progression. In this review, we will summarize the recent advances in the biology of this receptor in cancer and give an account of PRLR antagonist development for the treatment of cancer."

Journal • Review • CNS Disorders • Colon Cancer • Colorectal Cancer • Endometrial Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immune Modulation • Immunology • Inflammation • Liver Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • PRLR

ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. (PubMed, BMC Cancer) - "Collectively the efficacy and safety profile of ABBV-176 suggest it may be an effective therapy across a broad range of breast cancers and other cancer types where PRLR is expressed with the potential to combine with other therapeutics including PARP inhibitors."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PRLR

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. (PubMed, Invest New Drugs) - P1 | "No responses were observed, although data were available from a small number of patients with variable tumor PRLR expression. This study was terminated after the dosing of 19 patients."

Clinical • Journal • P1 data • Breast Cancer • Colorectal Cancer • Fatigue • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Disorders • Neutropenia • Oncology • Thrombocytopenia